Transfection Technologies Market Report 2024

This Transfection Technologies market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The transfection technologies market size has grown strongly in recent years. It will grow from $1.11 billion in 2023 to $1.21 billion in 2024 at a compound annual growth rate (CAGR) of 8.9%. The growth observed during the historical period can be attributed to several key factors, including the increasing prevalence of chronic diseases, the expanded applications of transfection technologies, a growing demand for cell and gene therapies, rising investments in research and development (R&D), and the increasing incidence of cancer.

The transfection technologies market size is expected to see strong growth in the next few years. It will grow to $1.7 billion in 2028 at a compound annual growth rate (CAGR) of 9%. The projected growth during the forecast period can be attributed to several factors, including the rising prevalence of chronic and immunological diseases, an increasing need for cell-based therapies, heightened demand for protein production, growing investments and funding in the development of drug delivery systems, and a rising demand for monoclonal antibodies. Key trends expected to influence this period include an increase in research and development focused on cell-based therapies, the adoption of technologically advanced transfection methods, greater demand for advanced therapeutic delivery systems, the increased use of dual-reporter assays and co-transfection experiments, and a heightened emphasis on personalized medicine.

The anticipated growth of the transfection technologies market is closely tied to the rising prominence of gene therapy. This innovative approach aims to treat or prevent diseases through gene modification, which encompasses the insertion, repair, or replacement of defective genes. The surge in gene therapy is propelled by advancements in genetic research, improved delivery methods, and its capacity to address previously untreatable genetic disorders. Transfection technologies play a pivotal role in gene therapy, enabling the precise, safe, and effective transfer of genetic material into cells. They facilitate both temporary and permanent modifications to the genome, which are crucial for treating genetic disorders and cancers. For example, a report from the American Society of Gene & Cell Therapy (ASGCT) and Citeline, published in July 2023, indicated that by the end of the first quarter (Q1) of 2023, there were 247 gene therapies in Phase II. This number saw a 5% increase, reaching 260 by the end of the second quarter (Q2). Thus, the expansion of gene therapy is a significant driver for the transfection technologies market.

Leading companies in the transfection technologies sector are prioritizing the development of advanced technologies, such as mechanoporation transfection systems, to facilitate more sophisticated and personalized applications in both research and therapeutic contexts. Mechanoporation systems utilize mechanical forces to create temporary openings in cell membranes, allowing for the efficient entry of genetic material. This minimally invasive method enhances cell viability while ensuring effective transfection. A notable example is the launch of CellPore by STEMCELL Technologies, a Canada-based biotechnology firm, in July 2024. This innovative transfection system features a benchtop unit alongside the CellPore Transfection Kit 300, which includes a specialized reagent kit and single-use delivery cartridges. By leveraging controlled, rapid deformation within microfluidic channels, CellPore efficiently delivers small molecules, nucleic acids, proteins, and gene editing complexes into cells, achieving minimal disruption and high viability. Such capabilities are essential for advancing research and developing state-of-the-art cell and gene therapies.

In July 2023, Sartorius Stedim Biotec, a French provider of biopharmaceutical and life science research solutions, announced the acquisition of Polyplus for an undisclosed sum. This acquisition is intended to enhance Sartorius’s biopharmaceutical portfolio by integrating cutting-edge cell and gene therapy technologies. The transaction expands Sartorius's offerings with essential components, including transfection reagents, plasmid design, and protein manufacturing. Polyplus, also based in France, specializes in the production of transfection reagents.

Major companies operating in the transfection technologies market are Thermo Fisher Scientific Inc., Lonza Group Ltd., Agilent Technologies Inc., Sartorius AG, Revvity Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Bio-Techne Corp., STEMCELL Technologies Inc., Promega Corporation, Takara Bio Inc., OriGene Technologies Inc., Applied Biological Materials Inc., MaxCyte Inc., New England Biolabs Inc., Cell Signaling Technology Inc., System Biosciences LLC, AMSBIO LLC, Altogen Biosystems, OZ Biosciences, Biontex Laboratories GmbH, RJH Biosciences Inc.

North America was the largest region in the transfection technologies market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transfection technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the transfection technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Transfection technologies refer to the intentional introduction of nucleic acids into cells through chemical, physical, or biological methods to modify gene expression or alter genetic content. These technologies are employed to study gene function, produce proteins, silence genes via RNA interference (siRNA/miRNA), and potentially treat genetic diseases by introducing functional genes.

The primary product types in transfection technology include kits and reagents, equipment, and other related items. Kits and reagents offer ready-to-use solutions that facilitate the introduction of nucleic acids into cells for various applications, such as gene expression and genome editing. Transfection is carried out using various methods, including lipofection, electroporation, nucleofection, cotransfection, cationic lipid transfection, and in-vivo transfection. These methods are applied in several areas, including virus production, protein production, gene silencing, stem cell reprogramming and differentiation, stable cell line generation, therapeutic delivery, and biomedical research. The end users of transfection technologies encompass pharmaceutical and biotechnology companies, contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), academic and research institutes, among others.

The transfection technologies market research report is one of a series of new reports that provides transfection technologies market statistics, including transfection technologies industry global market size, regional shares, competitors with a transfection technologies market share, detailed transfection technologies market segments, market trends, and opportunities, and any further data you may need to thrive in the transfection technologies industry. These transfection technologies market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The transfection technologies market consists of revenues earned by entities by providing services such as gene expression analysis, gene editing and therapy, and cell line development. The market value includes the value of related goods sold by the service provider or included within the service offering. The transfection technologies market also includes sales of transfection buffers, viral vectors, cell sorting and detection tools, and nanoparticles. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.